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In cell culture, cidofovir (CDV) was used to select a human cytomegalovirus (HCMV) strain with decreased drug
susceptibility. The genotypic characterization of this virus revealed a single base substitution resulting in a K513N amino acid
alteration in the viral DNA polymerase (UL54). Performed in parallel, the selection of HCMV for replication in the presence
of ganciclovir (GCV) selected an M460V substitution in the phosphotransferase (UL97), as well as a K513N/V812L double
substitution in DNA polymerase. Neither of the two DNA polymerase mutations has been previously identified in HCMV
drug-resistant strains. To precisely elucidate their role in drug resistance, corresponding recombinant mutant viruses were
generated by recombination of nine overlapping viral DNA fragments. The K513N recombinant virus showed 13- and 6.5-fold
decreased susceptibility to CDV and GCV in vitro, respectively, compared with the wild-type recombinant virus. Mutation
V812L was associated with a moderate (2–3-fold) decrease in susceptibility to CDV, GCV, foscarnet, and adefovir. A
multiplicative interaction of the K513N and V812L mutations with regard to the profile and level of drug resistance was
demonstrated in recombinant virus expressing both mutations. In vitro replication kinetic experiments revealed that the
K513N mutation significantly decreased HCMV replication capacity. Consistent with this finding, the K513N mutant DNA
polymerase exhibited reduced specific activity in comparison with the wild-type enzyme and was severely impaired in its
39-59 exonuclease function. Unexpectedly, the K513N mutant enzyme showed no decrease in susceptibility to CDV-
diphosphate or GCV-triphosphate. However, the K513N mutation decreased the susceptibility to CDV and GCV of the oriLyt
plasmid replication in the transient transfection/infection assay, suggesting that the DNA replication of the K513N mutant
virus is less sensitive to the corresponding inhibitors. © 1998 Academic Press
INTRODUCTION
Since the beginning of the acquired immune defi-
ciency syndrome (AIDS) epidemic, human cytomegalovi-
rus (HCMV) has been a major infectious pathogen, caus-
ing retinitis and other opportunistic diseases in a signif-
icant number of the patients with late-stage AIDS
(Jacobson and Mills, 1988). Although recent progress in
the treatment of human immunodeficiency virus infec-
tions has resulted in a marked decline in the incidence of
opportunistic diseases, HCMV infections remain a con-
cern in patients with AIDS. In addition, after bone marrow
or solid organ transplantation, immunosuppressed pa-
tients may have HCMV infections (Rubin, 1990), requiring
either anti-HCMV prophylaxis or treatment. However,
due to the chronic character of anti-HCMV therapy, re-
sistance may develop, which has been associated with
clinical failure and disease progression (Erice et al.,
1989; Wolf et al., 1995).
Resistance to ganciclovir (GCV), one of the three cur-
rently approved anti-HCMV drugs (Crumpacker, 1996),
has been shown to be associated with specific se-
quence alterations in the viral UL97 gene (Sullivan et al.,
1992; Biron and Baldanti, 1996; Baldanti et al., 1998). The
product of this gene has been proposed to catalyze the
first step in the metabolic activation of GCV (Littler et al.,
1992). In addition, specific mutations in the HCMV DNA
polymerase gene (UL54) confer decreased susceptibility
to GCV. The presence of UL54 alterations only in GCV-
resistant strains is rare; most often, they are present in
combination with at least one UL97 mutation (Biron and
Baldanti, 1996; Smith et al., 1997; Sullivan et al., 1993).
Viruses with both UL54 and UL97 mutations are selected
primarily during extended GCV therapy and exhibit high-
level GCV resistance (Smith et al., 1997).
Cidofovir (CDV) and foscarnet (PFA) are two additional
clinically available drugs for the treatment of HCMV in-
fections (Crisp and Clissold, 1991; Lalezari, 1997). When
PFA was administered as a first-line therapy, selection of
resistant viruses was not detected (SOCA, 1997). How-
ever, PFA-resistant strains carrying specific genotypic
alterations in the UL54 gene can arise when PFA treat-
ment follows GCV therapy (Baldanti et al., 1995a, 1996;
Chou et al., 1997). Generation of CDV-resistant strains
during CDV therapy has not been reported to date (Cher-
rington et al., 1996, 1998). However, strains with de-
creased susceptibility to GCV due to UL54 mutations
exhibit cross-resistance to CDV (Lurain et al., 1992; Smith
et al., 1997; Sullivan et al., 1993). On the other hand,
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because CDV is activated through phosphorylation cat-
alyzed by cellular enzymes (Cihlar and Chen, 1996), UL97
mutants resistant to GCV still remain susceptible to CDV
(Smith et al., 1997).
All three currently available anti-HCMV drugs target
viral DNA polymerase. Both CDV-diphosphate (CDVpp)
and GCV-triphosphate (GCVppp), the active metabolites
of the respective drugs, are effective competitive poly-
merase inhibitors (Hitchcock et al., 1996; Mar et al.,
1985a). PFA, on the other hand, functions directly as a
noncompetitive inhibitor (O¨berg, 1989).
Additional antiviral drugs targeting HCMV DNA poly-
merase are being evaluated in clinical trials. Among
them, adefovir [ADV; 9-(2-phosphonomethoxyethyl)ad-
enine] and lobucavir (LBV; cyclobut-G) efficiently sup-
press HCMV replication in vitro, and their active forms,
ADV-diphosphate and LBV-triphosphate, have been
shown to be potent inhibitors of HCMV DNA polymerase
(Tenney et al., 1997; Xiong et al., 1997a). It has been
demonstrated by generation and characterization of re-
combinant viruses that specific UL54 mutations can de-
crease virus susceptibility to either of these two agents
(Cihlar et al., 1998).
In vitro selection of viruses with decreased drug sus-
ceptibility is a useful tool for mapping drug resistance-
associated genotypic alterations, evaluating cross-resis-
tance profiles, and elucidating molecular mechanisms of
antiviral activity. HCMV strains selected in cell culture in
the presence of GCV were shown to harbor both UL97
and UL54 mutations (Lurain et al., 1992; Sullivan et al.,
1993). In the UL54 gene, point mutations leading to
F412V, L501I, or A987G amino acid substitutions in DNA
polymerase were identified in independently selected
viruses. These mutations also resulted in cross-resis-
tance to CDV (Lurain et al., 1992; Sullivan et al., 1993).
However, no detailed genotypic and phenotypic charac-
terization of a resistant HCMV strain selected by CDV
has been presented to date.
In this study, we describe an in vitro selection of drug-
resistant HCMV in the presence of CDV. For comparison, a
simultaneous selection in the presence of GCV was per-
formed. Genotypic alterations in the selected viral strains
were identified and their association with drug resistance
was confirmed by generation of corresponding mutant re-
combinant viruses. Characterization of these recombinants
revealed that the mutation selected for by CDV diminished
HCMV replication capacity in cell culture. In addition, fur-
ther data concerning the molecular mechanisms of CDV
resistance are presented.
RESULTS
Mutation K513N in the UL54 gene is selected in vitro
by both CDV and GCV
To characterize the molecular aspects of CDV resis-
tance, an HCMV strain with decreased susceptibility to
CDV was selected in cell culture. For comparison, a
parallel selection in the presence of GCV was also per-
formed. In the initial step, laboratory strain AD169 was
cultured in the presence of 0.5 mM CDV or 3 mM GCV
(i.e., at drug concentrations corresponding approxi-
mately to their respective IC50 values). Over a period of
10 months, the viruses were passaged every 7–14 days,
when significant cytopathic effect was observed. The
drug concentrations were gradually increased every sec-
ond to fourth passage depending on the level of virus
replication. After ;20 passages in the presence of CDV,
a virus was obtained that was able to replicate at 16 mM
CDV, which is 32-fold higher than the CDV IC50 value of
the parental virus. An equal number of passages in the
presence of GCV selected for a virus replicating at 300
mM GCV (i.e., at concentration exceeding 60-fold the
GCV IC50 value for the parental AD169 strain). From each
of these independently selected virus pools, two strains
were isolated by four rounds of plaque purification and
assayed for their susceptibility to CDV and GCV. Table 1
shows that the strains selected for by CDV (CDV.R1 and
CDV.R2) exhibited a 16–24-fold and ;10-fold reduced
susceptibility to CDV and GCV, respectively. Compara-
tively, the GCV-selected strains (GCV.R1 and GCV.R2)
demonstrated more significant decrease in their suscep-
tibility to both CDV (20–32-fold) and GCV (55–60-fold).
Genotypic analysis revealed an identical G-to-T mutation
at nucleotide 1539 in the UL54 gene from both CDV- and
GCV-selected strains compared with the AD169 se-
quence. This alteration results in a Lys-to-Asn substitu-
tion at codon 513 located in the polymerase conserved
d-region C (Fig. 1). In addition, both the GCV-selected
strains also carried a G-to-T mutation at nucleotide 2434
corresponding to a Val-to-Leu amino acid alteration at
codon 812 residing within the UL54 conserved region III.
Sequencing of the UL97 phosphotransferase gene re-
vealed an ATG (Met)-to-GTG (Val) substitution at codon
TABLE 1
Drug Susceptibilities of HCMV Strains Selected
in Vitro by CDV or GCV
Virus
IC50 (mM)
a
CDV GCV
AD169 0.5 5.0
CDV selected
CDV.R1 12 (24)b 50 (10)
CDV.R2 8 (16) 55 (11)
GCV selected
GCV.R1 10 (20) 275 (55)
GCV.R2 16 (32) 300 (60)
a The IC50 values represent the mean from at least four independent
determinations. In all cases, the standard error was ,35%.
b The numbers in parentheses indicate the fold increase above the
corresponding IC50 value of the parental AD169 strain.
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460 in both the GCV.R1 and GCV.R2 viruses. As expected,
no mutation was detected in the UL97 gene of the
CDV.R1 or CDV.R2 virus.
Mutation K513N is associated with both CDV and
GCV resistance
Although the K513E and K513R substitutions in the
UL54 gene were identified previously in HCMV strains
with decreased drug susceptibility (Smith et al., 1997),
the K513N is a novel alteration that has not been identi-
fied before in any drug-resistant isolate. Likewise, the
V812L mutation has not been previously described. To
precisely elucidate the association of these two UL54
substitutions with drug resistance, recombinant viruses
expressing independently each of these alterations were
constructed, and their drug susceptibility profiles were
determined. The data in Table 2 show that an introduc-
tion of the K513N mutation into the UL54 gene resulted in
a ;13- and 6-fold decrease in the virus susceptibility to
CDV and GCV, respectively, compared with the recombi-
nant virus with WT UL54 gene. When tested against ADV,
the K513N recombinant virus exhibited a 3-fold increase
in susceptibility to ADV compared with the wild-type (WT)
virus. On the other hand, the V812L substitution con-
ferred moderate, 2- to 3-fold decrease in susceptibility to
CDV, GCV, PFA, and ADV. Interestingly, both the K513N
and V812L mutant viruses remained WT with respect to
their susceptibility to LBV.
To accurately examine the mutual interaction of
the K513N and V812L mutations as well as the contri-
bution of the K513N/V812L double mutation to the final
drug resistance of GCV.R1 and GCV.R2, a recombinant
virus expressing both of these alterations was gener-
ated. The drug susceptibility assays revealed 10-fold
reduced susceptibility to GCV and a .30-fold de-
crease in sensitivity to CDV compared with the WT
FIG. 1. Amino acid substitutions in HCMV DNA polymerase selected in vitro by CDV or GCV. In the linear map of polymerase polypeptide, conserved
regions (I-VII and d-region C) and exonuclease domains (Exo I-III), respectively, are shown. Their boundaries with respect to amino acid numbering
of HCMV DNA polymerase have been defined as follows (Bernad et al., 1988; Blanco et al., 1991; Hwang et al., 1992; Simon et al., 1991; Wong et al.,
1988; Zhang et al., 1988): IV (379–421), d-region C (492–587), II (696–742), VI (771–790), III (805–845), I (905–919), VII (962–970), V (978–988), ExoI
(295–312), ExoI9 (376–393), ExoII (404–418), and ExoIII (533–545). The alignment of amino acid sequences with boxes showing homology at mutated
codons is based on previously published data (Ito and Braithwaite, 1991; Wong et al., 1988; Zhang et al., 1991).
TABLE 2
Drug Susceptibilities of Recombinant HCMVs Expressing UL54 Mutations Selected by CDV and GCV
UL54 substitution
IC50 (mM)
a
CDV GCV PFA ADV LBV
None 0.75 3.5 45 42 3.8
K513N 9.4 (12.5)b 21 (6.0) 50 (1.1) 14 (23.0) 3.5 (0.9)
V812L 2.4 (3.2) 8.8 (2.5) 130 (2.9) 122 (2.9) 5.7 (1.5)
K513N/V812L 25.5 (34) 34 (9.8) 135 (3.0) 26 (21.6) 3.8 (1.0)
a Average from at least three determinations with two independently generated recombinant viruses. In all cases, the standard error was ,35%.
b Underlined numbers indicate a significant (i.e., at least 2-fold) change in HCMV drug susceptibility. Positive and negative numbers in parentheses
represent fold increase and decrease, respectively, in IC50 value relative to the recombinant virus with wild-type UL54 sequence.
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recombinant (Table 2). In addition, this recombinant
mutant virus exhibited a 3-fold increase in PFA IC50
value, which represents a shift in PFA susceptibility
similar to that associated with the V812L mutation
alone. Overall, these data suggest a multiplicative
interaction of K513N and V812L mutations with respect
to the final drug susceptibility of the K513N/V812L
double mutant virus.
The K513N mutant virus is replication impaired
in cell culture
Because DNA polymerase is an essential enzyme for
HCMV replication, specific mutations in the UL54 gene
could influence the virus replication capacity. Compared
with the WT virus, certain PFA-resistant HCMV mutants
harboring UL54 mutations were found to replicate slower
in cell culture (Baldanti et al., 1996). Similarly, herpes
simplex virus type 1 (HSV-1) strains carrying specific
mutations in the DNA polymerase gene also exhibited a
slow-growth phenotype in vitro (Hwang et al., 1997).
Based on these findings, the influence of the CDV-se-
lected K513N polymerase alteration on the rate of HCMV
replication in cell culture was examined.
In the replication kinetic experiments, production of
extracellular virus was determined after infection of nor-
mal human dermal fibroblasts (NHDFs) with either the
WT or K513N mutant recombinant. Rather than perform-
ing a single-cycle replication experiment after a high
m.o.i., the cells were infected at a lower m.o.i., and virus
production was determined during several rounds of
viral replication. Figure 2 shows a comparison of the
yield of both viruses during a period of 15 days after
infection. The first increase in the level of extracellular
virus was detectable at day 5. Subsequently, production
of both viruses gradually increased, reaching a plateau
by day 9. However, during the entire experiment, two
independently generated K513N mutant recombinants
showed a markedly lower level of virus production com-
pared with the two WT recombinants, indicating that the
K513N mutation decreased in vitro HCMV replication
capacity.
K513N DNA polymerase exhibits reduced specific
activity and lacks the 39-59 exonuclease activity
To further study the molecular mechanism of the
K513N mutant slow replication phenotype, functional
characterization of the K513N DNA polymerase was un-
dertaken. The WT and K513N enzymes were isolated
from cells infected with the corresponding recombinant
virus using a standard, reproducible procedure that has
been previously shown to yield highly purified protein
(Mar et al., 1985b). In addition, both enzymes were ex-
pressed using a coupled in vitro transcription/translation
system (Cihlar et al., 1997). The in vitro expression in
reticulocyte lysate was successfully used by others for
characterization of mutant forms of HCMV DNA polymer-
ase (Ye and Huang, 1993) and HSV-1 DNA polymerase
(Dorsky and Crumpacker, 1988). Figure 3 shows the
immunoblot analysis of the WT and K513N mutant en-
zyme isolated from virus infected cells as well as the
sodium dodecyl sulfate–polyacrylamide electrophoresis
(SDS–PAGE) analysis of the in vitro expression products.
Both in the native enzyme preparations and in the in vitro
expression reactions, DNA polymerase protein with a
molecular mass of 140 kDa was detected with no appar-
ent differences between the WT and mutant proteins.
To compare the catalytic capacity of the WT and K513N
enzyme, a relative amount of both proteins was deter-
mined. Enzymes isolated from infected cells and in vitro
expressed enzymes were quantified by using the immu-
noblot assay and direct autoradiography of 35S-labeled
proteins, respectively. Both assays exhibited a linear
response in the range of protein quantification (Fig. 4).
Determination of the DNA-dependent DNA polymerase
activity with an identical amount of the WT and K513N
enzyme revealed that both the isolated and in vitro ex-
pressed K513N polymerase showed lower relative spe-
cific activity compared with the corresponding WT en-
zymes (Table 3). The difference between the WT and
K513N polymerase was more pronounced in the case of
the in vitro expressed enzymes; this may be due to the
fact that the purification procedure yields a complex
FIG. 2. Influence of the K513N polymerase substitution on HCMV replication capacity in cell culture. Confluent NHDFs in 12-well plates were
infected either with the WT (f) or K513N (M) recombinant HCMV at 50–60 pfu/well, and the yield of extracellular virus was compared by titration of
culture media. (a) and (b) show the representative growth kinetics of independently generated recombinants.
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consisting of the UL54 catalytic subunit and the UL44
accessory protein (Mar et al., 1985b), whereas only the
UL54 catalytic subunit was expressed in the reticulocyte
lysate. It has been shown that the accessory protein may
modify polymerase activity under certain conditions (Ertl
and Powell, 1992; Weiland et al., 1994).
The polymerase region between amino acids 532 and
545 was identified as an ExoIII domain and based on
homology with other replicative DNA polymerases was
suggested to participate in the 39-59 exonuclease func-
tion of the enzyme (Bernad et al., 1989; Blanco et al.,
1991). Because codon 513 is located in close vicinity to
this region and it codes for an amino acid conserved
among several other DNA polymerases (Fig. 1) (Zhang et
al., 1991), the 39-59 exonuclease activity of the WT and
K513N mutant polymerase also was determined. The WT
polymerase, both isolated from virus-infected cells and in
vitro expressed, was capable of releasing [3H]dTMP from
the 39-end of [3H]oligo(dT) attached to linear double-
strand DNA. However, the in vitro expressed K513N mu-
tant enzyme exhibited exonuclease activity at ;2% of the
level of the expressed WT enzyme, and the native K513N
enzyme isolated from infected cells showed undetect-
able exonuclease activity (Table 3). These data indicate
that the K513N substitution severely compromises the
exonuclease function of HCMV DNA polymerase as well
as affects its DNA-dependent DNA polymerase activity.
FIG. 3. Analysis of native isolated and in vitro expressed HCMV DNA
polymerases. (a) After separation of enzyme aliquots by SDS–PAGE,
immunoblot analysis with chemiluminescent detection of isolated en-
zymes was performed. The arrow indicates the 140-kDa polymerase
protein. (b) Direct analysis of [35S]methionine-labeled in vitro ex-
pressed enzymes after SDS–PAGE separation.
FIG. 4. Linear response of the assays used for relative quantitation of the WT () and K513N mutant () HCMV DNA polymerase. (a) Varying
amounts of enzymes isolated from virus-infected cells were separated on SDS–PAGE and electroblotted onto a polyvinylidene difluoride membrane.
Subsequent immunoblot analysis and quantification was performed as described in Materials and Methods. (b) In vitro expression of both enzymes
was performed in the presence of [35S]methionine, and varying amounts of the expression reactions were separated on SDS–PAGE. The fixed and
dried gel was scanned using the PhosphorImager system, and the bands corresponding to the full-length UL54 proteins were quantified.
TABLE 3
Functional Comparison of the WT and K513N Mutant HCMV
DNA Polymerase
Enzyme
Activity (units)a
DNA Polymerase 39–59 Exonuclease
Isolated from infected cellsb
WT 4.9 6 0.9 (100%) 6.5 6 1.1 (100%)
K513N 3.0 6 0.5 (61%) 0 (0%)
In vitro expressedc
WT 6.5 6 1.1 (100%) 5.3 6 1.3 (100%)
K513N 1.5 6 0.5 (23%) 0.11 6 0.06 (2%)
a One unit of the DNA polymerase and 1 unit of the 39–59 exonucle-
ase activity corresponds with the incorporation of 1 pmol of dGTP into
activated calf thymus DNA and with release of 1 pmol of dTMP from the
single-stranded DNA substrate, respectively, per 1 h under the condi-
tions specified in Materials and Methods. The data represent the mean
with standard error values from two independent experiments.
b Enzymes isolated from infected cells were quantified by using the
immunoblot assay as described in Materials and Methods. An equal
amount of the WT and K513N mutant enzyme was used for their
functional comparison.
c Quantification of the in vitro expressed enzymes was performed by
direct autoradiography of the 35S-labeled proteins as described in
Materials and Methods. An equal amount of the WT and K513N mutant
enzyme was used for their functional comparison. The background
DNA polymerase and 39–59 exonuclease activities detected in the
reticulocyte lysate accounted for ,5% of those of the WT enzyme. The
numbers represent values after subtraction of the corresponding back-
ground activities.
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The K513N mutation decreases susceptibility of viral
DNA replication to CDV and GCV
Using the enzymes isolated from cells infected with
corresponding recombinant viruses, we investigated a
potential correlation between the decreased drug sus-
ceptibility of the K513N mutant virus and the sensitivity of
the K513N mutant polymerase toward corresponding in-
hibitors. Steady-state kinetic experiments were per-
formed to determine the Km values for dNTPs and the Ki
values for CDVpp, GCVppp, PFA, and ADVpp. Enzyme
sensitivities toward the inhibitors were compared based
on the corresponding ratios of Ki to Km.
Unexpectedly, no significant differences between the
WT and K513N enzyme, particularly with regard to their
sensitivities to CDVpp and GCVppp were found (Table 4).
Similarly, no differences in drug susceptibility were found
between the enzymes isolated from cells infected with
the parental strain AD169 and the strain CDV.R1 (data not
shown). To clarify whether this lack of correlation be-
tween virus and enzyme drug susceptibility was a more
general HCMV phenomenon, drug susceptibility of the
V715M mutant polymerase was characterized. It was
shown previously that the V715M substitution conferred
10- and 5-fold decreased susceptibility to PFA and ADV,
respectively (Baldanti et al., 1996; Cihlar et al., 1998). The
enzyme was isolated from cells infected with the corre-
sponding recombinant V715M mutant virus. In the en-
zyme preparation, a 140-kDa polymerase protein identi-
cal to that in the WT and K513N enzyme preparation was
detected by immunoblot assay (data not shown). Inter-
estingly, data in Table 4 show that the V715M mutant
enzyme was ;9- and ;4-fold less susceptible to PFA
and ADVpp, respectively, compared with the WT poly-
merase.
The WT drug susceptibility of the K513N mutant poly-
merase observed in the activated DNA-based assay in-
dicates that the mutation does not modify the ability of
the enzyme to elongate DNA in the presence of inhibitor.
However, viral DNA replication occurring during the
HCMV life cycle is a complex process directly involving
at least six viral proteins (Pari et al., 1993a). The assay
using enzymes isolated from infected cells may not fully
reflect this level of complexity; therefore, we used the
transient transfection/infection assay to compare drug
susceptibilities of DNA synthesis of the WT and K513N
recombinant virus during their normal replication cycle.
In this assay, intracellular replication of a plasmid pSP50
containing the origin of HCMV lytic-phase DNA replica-
tion (oriLyt) is driven by viral proteins provided in trans by
HCMV infection (Anders et al., 1992), and its sensitivity to
antiviral agents can be quantitatively determined. Figure
5 shows that the plasmid replication after infection with
the K513N mutant was 10- and 4-fold less susceptible to
CDV and GCV, respectively, compared with plasmid rep-
lication in the presence of WT virus. In contrast, there
was no difference in the susceptibility to PFA. These data
suggest that the K513N mutation diminishes the sensi-
tivity of viral DNA replication to CDV and GCV but not to
PFA, which correlates with the drug susceptibility phe-
notype of the K513N mutant virus.
DISCUSSION
To date, selection of CDV-resistant strains during CDV
therapy has not been reported; therefore, the primary
goal of this work was to determine whether CDV could
select for a resistant HCMV strain in vitro. Because it has
been previously shown that HCMV strains containing
UL54 mutations selected by GCV exhibit cross-resis-
tance to CDV (Lurain et al., 1992; Snoeck et al., 1996;
Sullivan et al., 1993), we concurrently carried out a par-
allel selection in the presence of GCV. Genotypic analy-
sis of the CDV- and GCV-selected strains revealed an
identical K513N amino acid substitution in viral DNA
polymerase. The GCV-selected virus also expressed the
V812L polymerase alteration. Furthermore, it carried the
M460V mutation in the UL97 gene, which has been
previously detected by others in a GCV-resistant clinical
isolate and was proved by marker transfer to confer a
5–6-fold decrease in susceptibility to GCV (Chou et al.,
1995). It has been shown in cell culture as well as in vivo
TABLE 4
Sensitivity of the WT and Mutant HCMV DNA Polymerases Towards Anti-HCMV Inhibitors
Enzyme
Km (mM)
a Ki (mM)
a
dCTP dGTP dATP CDVpp GCVppp PFA ADVpp
WT 0.26 0.24 0.66 1.2 0.085 3.5 0.074
(4.6)b (0.35) (14.6) (0.11)
K513N 0.31 0.26 0.38 1.5 0.11 3.6 0.044
(4.8) (0.42) (13.8) (0.12)
V715M 0.78 0.39 1.14 2.9 0.25 45 0.48
(3.7) (0.62) (123) (0.42)
a The data are averages from at least two independent experiments.
b The numbers in parentheses represent Ki/Km values.
387SLOW REPLICATION PHENOTYPE OF HCMV Pol MUTANT
FIG. 5. Susceptibility to CDV, GCV, and PFA of pSP50 (oriLyt) plasmid replication after infection with either WT or K513N mutant recombinant virus.
(a) The level of pSP50 plasmid replication in the presence of various concentrations of CDV (lane 1, no drug; lanes 2–5, 0.5, 1.5, 5, and 15 mM), GCV
(lane 1, no drug; lanes 2–5, 2, 6, 20, and 60 mM) and PFA (lane 1, no drug; lanes 2–5, 6, 20, 60, and 200 mM) was determined by the transient
transfection/infection assay. The arrow indicates the intracellularly replicated pSP50 plasmid resistant to DpnI digestion. (b) Drug dose-response
curves and IC50 values for inhibition of pSP50 replication after infection with the WT (F) and K513N (E) recombinant viruses.
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that GCV is capable of selecting for viruses with muta-
tions in both the UL97 and UL54 gene (Sullivan et al.,
1993; Chou et al., 1997; Smith et al., 1997). However, this
is the first reported example of a selection in the pres-
ence of GCV that resulted in a combination of two alter-
ations in DNA polymerase in addition to a UL97 mutation.
Recently, a detailed study of drug resistance-associ-
ated mutations in the UL54 gene revealed that most of
the alterations conferring the same drug resistance phe-
notype cluster within specific DNA polymerase con-
served regions. Alterations located in region IV and d-re-
gion C were found to specifically confer CDV/GCV resis-
tance and ADV hypersensitivity (Cihlar et al., 1998).
Characterization of the K513N mutation located in d-re-
gion C supports these findings. Previously, other variants
of codon 513 (K513E and K513R) were identified in drug-
resistant clinical isolates (Smith et al., 1997). It is note-
worthy that the recombinant virus expressing the K513E
substitution exhibited CDV and GCV resistance and ADV
hypersensitivity at similar levels as those observed for
the K513N mutant recombinant virus (Cihlar et al., 1998).
The V812L substitution conferring a moderate de-
crease in susceptibility to CDV, GCV, PFA, and ADV
resides in the UL54 conserved region III (Fig. 1), in which
at least four other HCMV drug resistance-associated
mutations have been identified to date. Contrary to sub-
stitutions in region IV, region II, and d-region C, the
mutations located in region III confer various phenotypes
ranging from decreased susceptibility to specific drugs
in some cases to drug hypersensitivity in others (Cihlar
et al., 1998).
Unexpectedly, further investigation of the molecular
mechanisms of HCMV drug resistance associated with
the K513N substitution revealed no significant differ-
ences between the K513N and WT DNA polymerase with
regard to their sensitivity to CDVpp and GCVppp. On the
contrary, an enzyme with the V715M mutation exhibited
decreased sensitivity to PFA and ADVpp but not to CDVpp
and GCVppp, which is in complete agreement with the
drug-susceptibility profile of the V715M mutant recombi-
nant virus (Baldanti et al., 1996; Cihlar et al., 1998). Thus,
drug resistance of the V715M mutant virus is likely
due to decreased affinity of the mutant polymerase to the
corresponding inhibitors. Although the K513N mutation
did not decrease polymerase affinity for CDVpp and
GCVppp, it did reduce the susceptibility to CDV and GCV
of the replication of the plasmid containing HCMV oriLyt
sequence. Thus, it is possible that the molecular mech-
anisms of resistance due to the K513N mutation involves
more complex interactions between the inhibitors and
HCMV DNA polymerase. Previously, primer extension
assays using native isolated WT polymerase revealed
that CDV can be internally incorporated into a DNA
primer (Xiong et al., 1997b), suggesting that it may also
be incorporated into viral DNA during HCMV replication.
This DNA may then serve as a template in the subse-
quent replication cycles of the virus. However, it has
been shown that DNA synthesis by the WT enzyme
proceeds very inefficiently on a template with internally
incorporated CDV molecules (Xiong et al., 1997b). The
K513N mutation may modify the ability of DNA polymer-
ase to use such a defective template. This type of differ-
ence between the WT and K513N enzyme would not be
detectable by the steady-state enzyme kinetic experi-
ments described here.
In the second part of the work, we attempted to char-
acterize additional functional consequences of the
K513N substitution. The replication kinetic experiments
disclosed an impairment in the replication capacity of the
K513N mutant recombinant virus. Because the drug re-
sistance-associated mutations at codon 513 are clinically
relevant (Smith et al., 1997), it would be interesting to
determine the in vivo replication capacity of the K513N
mutant virus. Unfortunately, it is not possible to address
this question due to inefficient replication of HCMV lab-
oratory strains in animal models. Notably, however, the
replications of drug-resistant HSV-2 and murine cyto-
megalovirus selected in vitro by CDV both showed se-
verely impaired pathogenicity when tested in animal
models (Mendel, D. B., Tai, C. Y., Barkhimer, D. B., Kern,
E. R., Chen, M. S., unpublished data; Smee et al., 1995),
suggesting that the K513N mutant may also replicate
more slowly in vivo.
The K513N mutant enzyme, both in vitro expressed and
isolated from virus-infected cells, was virtually deficient
in the 39-59 exonuclease function. These data demon-
strate that HCMV with impaired 39-59 exonuclease activ-
ity is still able to replicate in cell culture, suggesting that
fully active 39-59 exonuclease may not be essential for in
vitro virus replication. Based on the homology with other
a-like DNA polymerases, it has been proposed that four
amino acid segments (designated domain ExoI, ExoI9,
ExoII, and ExoIII, respectively) located in the N-terminal
portion of HCMV DNA polymerase form the 39-59 exonu-
clease active site (Fig. 1) (Bernad et al., 1989; Blanco et
al., 1991; Simon et al., 1991). Specific mutations within the
Exo motifs of bacterial, yeast, or viral DNA polymerases
can impair the 39-59 exonuclease function (Hall et al.,
1995; Ku¨hn and Knopf, 1996; Morrison et al., 1991; Simon
et al., 1991). However, residue 513 in HCMV polymerase
is the first identified amino acid located outside the
known exonuclease domains that is important for retain-
ing the 39-59 exonuclease activity. The fact that this
amino acid is conserved among several DNA poly-
merases containing d-region C indicates that it may play
a direct role in enzyme catalytic functions.
Notably, HSV-1 strains carrying specific mutations in
d-region C within the ExoIII domain of the DNA poly-
merase gene exhibited not only a lower replication
capacity in cell culture but also significantly higher
mutational frequency due to a severely impaired 39-59
exonuclease function (Hwang et al., 1997). In addition,
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site-directed mutagenesis studies of the exonuclease
domains in bacterial and yeast DNA polymerases
demonstrated the importance of 39-59 exonuclease
function for the fidelity of DNA replication (Morrison et
al., 1991; Simon et al., 1991). Based on these findings,
it is believed that the 39-59 exonuclease activity of all
replicative DNA polymerases exerts a proofreading
function during the process of DNA synthesis (Echols
and Goodman, 1991). Thus, the 39-59 exonuclease de-
ficiency that may exist in some of the drug-resistant
HCMV mutants may increase their mutational fre-
quency and facilitate the subsequent selection of ad-
ditional drug resistance-associated mutations.
In summary, this work represents a comprehensive
characterization of a drug-resistant HCMV variant se-
lected in the presence of CDV. The UL54 mutation iden-
tified in this variant markedly compromised the in vitro
replication capacity of the mutant virus. Although the
effect of drug resistance-associated UL54 mutations on
the in vivo virus replication is not fully understood at this
time, the results of this study suggest that certain HCMV
UL54 mutant variants may have in vivo limited replication
capacity. These variants may not arise readily during the
antiviral therapy, and if so, they may exhibit reduced
pathogenicity.
MATERIALS AND METHODS
Cells and viruses
NHDFs obtained from Clonetics (San Diego, Califor-
nia) were maintained in Eagle’s minimum essential
medium supplemented with 10% fetal bovine serum,
nonessential amino acids, 100 U/ml penicillin, and 100
mg/ml streptomycin. The cells were not used for .10
passages. HCMV strain AD169, obtained from Ameri-
can Type Culture Collection (ATCC VR-538; Rockville,
Maryland), as well as all of the generated HCMV
strains, were grown in NHDFs.
Generation of recombinant mutant viruses
The recombinants were constructed by an approach
based on intracellular homologous recombination of nine
overlapping viral DNA fragments after their cotransfection
into permissive cells (Cihlar et al., 1998). Cosmids contain-
ing seven of these viral DNA fragments were kindly pro-
vided by George Kemble from Aviron (Mountain View, Cal-
ifornia). Plasmids with each of the remaining two DNA
fragments (7.4 and 12 kbp) were constructed as described
previously (Cihlar et al., 1998). The mutations of interest
were introduced into the UL54 gene residing within the
7.4-kbp DNA fragment by a two-step polymerase chain
reaction (PCR) amplification procedure (Cihlar et al., 1998).
For introduction of the K513N mutation, a pair of mutagenic
primers 59-CGGCAACGCAATGATGACCTGTCTTAC-39/59-
GTAAGACAGGTCATCATTGCGTTGCCG-39 was used. The
V812L mutation was incorporated into the UL54 gene using
primers 59-GGCGCTCAAATTAACGTGCAACGCTTTC-39 and
59-GAAAGCGTTGCACGTTAATTTGAGCGCC-39. The un-
derlined bases indicate the mutation sites. For genera-
tion of the K513N/V812L recombinant virus, the two mu-
tations were introduced sequentially. After cloning the
PCR products into the 7.4-kbp DNA fragment, the correct
nucleotide sequence of the entire region amplified by
PCR was verified by sequence analysis of both DNA
strands. To generate each recombinant virus, the 7.4-kbp
DNA fragment carrying the corresponding mutation was
transfected by calcium phosphate precipitation into em-
bryonic lung fibroblasts together with eight other over-
lapping HCMV DNA fragments. The genotype of each
recombinant virus was verified by sequencing after PCR
amplification of the UL54 gene.
Drug susceptibility assays
The standard plaque reduction assay in a 24-well plate
format was used to determine virus sensitivities to CDV
(Gilead Sciences, Foster City, CA), GCV (Hoffmann-La
Roche, Nutley, New Jersey), PFA (Sigma Chemical, St.
Louis, Missouri), ADV (Gilead Sciences), and LBV (Bris-
tol-Myers Squibb, Wallingford, CT) (Cherrington et al.,
1996). Briefly, NHDFs infected with 30–60 plaque-forming
units (pfu)/well were incubated for 5–8 days in either the
absence or presence of drug at various concentrations.
The plates were stained with 0.1% crystal violet in 20%
methanol, and the number of plaques was visually de-
termined and expressed as a percentage of the plaques
detected in the absence of drug. The IC50values were
determined from the semilogarithmic plot of plaque per-
centage versus drug concentration.
In vitro replication kinetic experiments
The replication capacity of the WT and K513N mutant
recombinants was compared based on the yield of ex-
tracellular virus after infection of NHDFs. To accurately
standardize the virus input, two parallel 12-well plates
were infected with 2-fold serially diluted inoculum of
each virus. Beginning on day 5 after infection, aliquots of
growth media were collected every 24 h from one plate
infected with each virus and stored at 270°C. In addi-
tion, at 5–7 days after infection, parallel plates were
stained with crystal violet and used for pfu determination.
Media collected from wells infected with identical input
of virus (50–60 pfu/well) were simultaneously titered for
the yield of recombinant viruses in 24-well plates using
10-fold serial dilutions. Two independently generated WT
and K513N mutant recombinants were tested in dupli-
cate. Before the growth kinetic experiments, the correct
genome structure of the recombinant viruses was veri-
fied by comparison of EcoRI and HindIII restriction digest
profiles of purified viral DNA.
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Enzymes
The WT, K513N, and V715M mutant polymerases were
isolated from virus-infected NHDFs using a previously
described procedure (Mar et al., 1985; Xiong et al.,
1997b). Fifteen roller-bottles (850 cm2) of confluent cells
were infected with the individual recombinant viruses at
an m.o.i. of 0.5. When most of the cells showed cyto-
pathic effect (usually 5–8 days after infection), cells were
harvested, washed in phosphate-buffered saline (PBS),
and solubilized in the presence of 0.03% Nonidet-P40.
After centrifugation at 100,000 g for 90 min, each enzyme
was isolated from the supernatant by four sequential
chromatographic steps on DEAE-Sephacel, phosphocel-
lulose, heparin-agarose, and single-stranded DNA aga-
rose. To improve the stability of the enzymes during the
purification, 0.2 mg/ml bovine serum albumin (BSA) was
added to each column fraction. The fractions were as-
sayed by the filter-based assay in the presence or ab-
sence of 90 mM (NH4)2SO4 using activated calf thymus
DNA (Xiong et al., 1997b). Active fractions stimulated by
the presence of salt were pooled for further purification.
After a final chromatography step, the enzymes were
concentrated using a Centriprep-10 (Amicon, Beverly,
Massachusetts) and stored in 10 mM KPO4, pH 8.0, 1 mM
EDTA, 2 mM dithiothreitol, 1 mg/ml BSA, and 30% glyc-
erol at 270°C.
The quality of enzyme preparations was examined by
immunoblot analysis. Enzymes were separated by elec-
trophoresis on an 8% polyacrylamide gel in the presence
of SDS and electroblotted onto a polyvinylidene difluo-
ride membrane (Millipore, Bedford, Massachusetts),
which was subsequently blocked in PBS/5% dry milk
(PBS-M) for 1 h, washed three times in PBS/0.05% Tween
20 (PBS-T), and incubated overnight in PBS-M with rabbit
antiserum raised against HCMV DNA polymerase (kindly
provided by Eng-Shang Huang, University of North Caro-
lina at Chapel Hill). After the wash in PBS-T, the mem-
brane was incubated in PBS-M with goat anti-rabbit
antibody conjugated to alkaline phosphatase (Zymed,
South San Francisco, California). After an additional
wash and incubation with a chemiluminescent substrate
(Amersham, Arlington Heights, Illinois), the immunoblot
was exposed to a x-ray film. Quantification of the en-
zymes isolated from infected cells was achieved by us-
ing identical conditions, except a Cy5-conjugated donkey
anti-rabbit antibody (Jackson Immunoresearch, West
Grove, Pennsylvania) was used instead of the alkaline
phosphatase conjugate. The relative amount of each
protein was determined after scanning the immunoblot
using the Storm 860 PhosphorImager system (Molecular
Dynamics, Sunnyvale, California).
In addition to isolation from infected cells, the WT and
K513N mutant polymerases also were expressed using
the coupled in vitro transcription/translation system
(Cihlar et al., 1997). Circular plasmids pUL54–6 (Cihlar et
al., 1997) containing either the WT or mutant UL54 gene
were simultaneously subjected to expression in the TNT
coupled reticulocyte lysate system (Promega, Madison,
Wisconsin) according to the manufacturer’s instructions.
To verify the expression of enzymes and determine their
relative quantity, the transcription/translation reactions
were carried out in the presence of [35S]methionine (Am-
ersham; specific activity, 1200 Ci/mmol), and their prod-
ucts were separated by SDS–PAGE. The fixed and dried
gel was scanned using the PhosphorImager system, and
the bands corresponding to the full-length UL54 proteins
were quantified.
Enzymatic assays
The DNA-dependent DNA polymerase activity of the
WT and K513N mutant enzyme was determined using the
filter-based assay (Cihlar et al., 1997). Reactions were
performed in a 60-ml volume and contained polymerase
buffer [20 mM Tris–HCl, pH 8.0, 90 mM (NH4)2SO4, 10
mM MgCl2, 0.5 mM dithiothreitol, 0.2 mg/ml BSA, 5%
glycerol]; 6 mg of activated calf thymus DNA, 0.5 mM
[3H]dGTP (Amersham; specific activity, 37 Ci/mmol); 10
mM concentration each of dATP, dCTP, and dTTP; and the
enzyme. The amount of the WT and K513N mutant poly-
merase in the reaction was standardized according to
their relative quantifications described above. After 10-,
20-, and 30-min incubations at 37°C, aliquots of each
reaction were removed and processed as described
(Cihlar et al., 1997). A linear time course of each reaction
was generated, and relative reaction rates were deter-
mined. One unit of enzymatic activity (1 U) was defined
as the amount of enzyme-catalyzing incorporation of 1
pmol of dGTP into activated calf thymus DNA per hour
under the specified conditions.
Identical assay conditions were used for determina-
tion of kinetic constants. Km values were measured in the
presence of 10 mM dNTPs and various concentrations of
the appropriate [3H]dNTP (Amersham; specific activity,
30 Ci/mmol). Determination of Ki values for CDVpp,
GCVppp, and PFA was carried out at four different inhib-
itor concentrations. Kinetic constants were calculated
from double-reciprocal plots of initial reaction rates us-
ing KinetAsyst software (Think Technologies, San Diego,
CA) based on published algorithms (Cleland, 1979).
The 39-59 single-stranded exonuclease activity was
assayed by measuring the release of [3H]dTMP from
[3H]oligo(dT) attached to the 39-end of linearized plasmid
DNA (Cihlar et al., 1997). Reactions were performed with
0.5 mCi of substrate (5 3 105 cpm/mg of DNA) in 60 ml of
polymerase buffer. After 10-, 20-, and 30-min incubations
at 37°C with a standardized amount of the WT or K513N
mutant enzyme, 15-ml sample aliquots were removed
and processed as described (Cihlar et al., 1997). Relative
reaction rates were determined from a linear time course
of each reaction.
391SLOW REPLICATION PHENOTYPE OF HCMV Pol MUTANT
Transient transfection/infection assay
The assay was carried out as described previously
(Cihlar et al., 1998). Briefly, the plasmid pSP50 containing
the HCMV origin of lytic replication (kindly provided by
Dr. Greg Pari, Hybridon, Cambridge, Massachusetts)
was transfected into NHDFs by CaPO4 precipitation (Pari
et al., 1993b). After transfection, the cells were infected
with either the WT or K513N mutant recombinant virus at
an m.o.i. of 10 and incubated in either the absence or
presence of various concentrations of CDV, GCV, or PFA.
Total DNA was purified from each sample 120 h after
infection, digested with EcoRI and DpnI, and separated
on a 0.7% agarose gel. DNA was then transferred onto a
Hybond-N1 membrane (Amersham) and probed with 32P-
labeled pGEM cloning vector (Promega) as described
previously (Cihlar et al., 1998). The membrane was first
exposed to x-ray film and then scanned using the Phos-
phorImager system. The bands corresponding to intra-
cellularly replicated full-length pSP50 were quantified
and expressed as a percentage of plasmid replication in
the absence of drug. The 50% inhibitory concentration
was determined for each drug from the semilogarithmic
plot of the percentage of plasmid replication versus drug
concentration.
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